Compare Sony Group Corp (SONY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs TransMedics Group Inc — how do they compare? Sony Group Corp trades at $24.26 (market cap $136.87B), while TransMedics Group Inc trades at $78.47 (market cap $2.74B). The key difference: Sony Group Corp is far larger — about 50× TransMedics Group Inc's market cap, and Sony Group Corp pays a 0.66% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sony Group Corp for 96 Days and TransMedics Group Inc for 24 Days on average.
| SONY | TMDX | |
|---|---|---|
Market Cap | $136.87B | $2.74B |
Volume | 5,364,503 | 949,331 |
Sector | Technology | Health |
52-Week High | $30.26 | $150.42 |
52-Week Low | $19.32 | $61.99 |
Typical Hold Time | 96 Days | 24 Days |
Enterprise Value | $134.77B | $3.13B |
Dividend Yield | 0.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony (SONY) trades at $24.24, up 3.06% with a bullish technical signal from moving averages. The company reported strong Q4 2025 and Q2 2026 earnings beats but missed Q1 2026 expectations. Revenue remains stable around $12.96T with improved net income of $1.14T in 2025, though 2026 projections show a net loss. Analyst consensus is strongly bullish with 11 buy ratings and no sell recommendations. Recent news highlights Sony's content strength and legal actions against AI copyright infringement.
Sony presents a mixed outlook with strong entertainment assets and improving cash flow offset by projected 2026 profitability challenges. The stock's current valuation metrics appear reasonable, but investors should monitor execution risks in content monetization and competitive pressures in the entertainment sector. The bullish analyst sentiment and technical momentum suggest near-term upside potential.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
